Hikma Pharmaceuticals Plc Director/PDMR Shareholding (0967F)
May 20 2013 - 4:42AM
UK Regulatory
TIDMHIK
RNS Number : 0967F
Hikma Pharmaceuticals Plc
20 May 2013
Hikma Pharmaceuticals PLC - LTIP Awards
LONDON, 20 May 2013: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) announces that, further to the approval of the
Ordinary Shareholders of Hikma obtained at the Company's Annual
General Meeting to make awards to the executive directors on 16 May
2013, the Remuneration Committee has made the following conditional
awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive
Plan (the "LTIP") to Persons Discharging Managerial Responsibility
("PDMR") of the Company.
Awards under the LTIP were made on 17 May 2013 at a price of
1,000 pence per Ordinary Share as follows:
Name of PDMR Number of LTIP Shares
Said Darwazah 102,000
Mazen Darwazah 53,000
Bassam Kanaan 40,000
Michael Raya 38,000
Khalid Nabilsi 22,000
Riad Mishlawi 22,000
The shares subject to the LTIP awards will only be released to
the participants in three years time, subject to their continued
employment and the satisfaction of the performance targets:
-- comparative Total Shareholder Return ("TSR")
-- Sales Growth
-- earnings per share ("EPS") growth
-- return on invested capital ("ROIC")
Half of the award is subject to TSR against the Comparator Group
and requires at least upper quartile performance to vest in full.
The remaining half is split equally between the financial targets
and requires sales growth of 13%, EPS growth of 20% and ROIC of 12%
to vest in full. Each target is measured individually and is
independent of the other targets. Further details on these
performance criteria and the LTIP can be found in Hikma's report
and accounts for the year ended 31 December 2012 on pages 96 to
99.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSGIGDUCXDBGXG
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024